Merck (MRK): VA awarded $96K

$96K

committed so far

Signed

Jan 13, 2026

Updated

Jan 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 13, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
2. Nov 18, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
3. Nov 21, 2025FDAFDA drug approval: Keytruda
4. Nov 21, 2025FDAFDA drug approval: Keytruda Qlex
5. Dec 12, 2025FDARecall: Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured…
6. Dec 12, 2025FDARecall: Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway…
7. Dec 18, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
8. Dec 19, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
9. Jan 13, 2026 · this disclosureFederal contract · $96K obligatedDepartment of Veterans Affairs awarded Merck: $96K obligated to date

What came next

1. Jan 27, 2026FDAFDA drug approval: Noxafil
2. Jan 27, 2026FDAFDA drug approval: Noxafil
3. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
4. Feb 4, 2026Insider · 4 peopleInsiders: 6 sales (~$13.2M)
5. Feb 4, 2026CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
6. Feb 5, 2026InsiderOfficer sold ~$2.44M of MRK shares in the open market
7. Feb 6, 2026Insider · 3 peopleInsiders: 3 sales (~$7.0M)
8. Feb 9, 2026Insider · 2 peopleInsiders: 4 sales (~$15.7M)
9. Feb 10, 2026FDAFDA drug approval: Keytruda
10. Feb 10, 2026FDAFDA drug approval: Keytruda Qlex
11. Feb 10, 2026InsiderOfficer sold ~$1.2M of MRK shares in the open market
12. Feb 12, 2026InsiderOfficer sold ~$1.21M of MRK shares in the open market
13. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
14. Apr 15, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
15. Apr 24, 2026FDAFDA drug approval: Keytruda Qlex
16. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
17. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
18. May 4, 2026Federal contract · $43K obligatedDepartment of Veterans Affairs awarded Merck: $43K obligated to date
19. May 8, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
20. May 11, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date

How to read USAspending.gov award record

The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.

Full guide: Contract ceiling vs obligated amount: the difference

What else is on file for Merck

For Merck, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

How this filing works

• Contract ceiling vs obligated amount

Other disclosures at Merck

• SEC Form 144Nov 12, 2026
• SEC Form 144Nov 2, 2026
• House Clerk periodic transaction reportOct 7, 2026
• USAspending.gov award recordSep 24, 2026
• USAspending.gov award recordSep 17, 2026
• House Clerk periodic transaction reportSep 9, 2026

Everything OQRO holds on this company is on its MRK page.